Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC

Trial Profile

Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Maraviroc (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MARAVI-PEP
  • Most Recent Events

    • 18 Mar 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 14 Mar 2012 Status changed from recruiting to completed, according to European Clinical Trials Database.
    • 14 Feb 2012 Additional lead trial center and investigator identiifed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top